Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KCNJ6 | P48051 | 15/20 | 0.34 |
| ▸ | KCNJ3 | P48549 | 15/20 | 0.34 |
| ▸ | KCNJ5 | P48544 | 11/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4782054 | 0.96 | L3MBTL1 (0.33) | L3MBTL1KCNJ6KCNJ3KCNJ5MAPT | |
| SCHEMBL4731703 | 0.93 | — | — | |
| SCHEMBL4781015 | 0.91 | L3MBTL1 (0.35) | L3MBTL1KCNJ6KCNJ3KCNJ5MAPT | |
| SCHEMBL14221380 | 0.87 | KCNJ6 (0.36) | KCNJ6KCNJ3KCNJ5MAPTKDM4E | |
| SCHEMBL4784718 | 0.85 | KDM1A (0.30) | — | |
| SCHEMBL4781499 | 0.84 | L3MBTL1 (0.39) | L3MBTL1KCNJ6KCNJ3KCNJ5MAPT | |
| SCHEMBL4919594 | 0.84 | — | — | |
| SCHEMBL4784279 | 0.83 | KDM1A (0.31) | — | |
| SCHEMBL14221381 | 0.83 | KCNJ6 (0.35) | KCNJ6KCNJ3KCNJ5MAPTKDM4E | |
| SCHEMBL4783839 | 0.80 | L3MBTL1 (0.36) | L3MBTL1KCNJ6KCNJ3KCNJ5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096950-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-04-24 | — | — | US | claimed |
| US-20080096950-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096950-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-04-24 | — | — | US | disclosed |
| WO-2008047224-A1 | PYRAZOLYL-4-OXY-BENZONITRILE DERIVATIVES USEFUL IN TREATING ENDOMETRIOSIS | PFIZER LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| US-20080096950-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096950-A1 | Compounds Useful In Therapy | CYP19A1, LPXN, HSD17B11 | L3MBTL1 4303/4885KCNJ6 3322/4885KCNJ3 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.